European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduced what it describes as the first once-daily oral peptide targeting IL-23R, designed to deliver skin clearance with a favorable safety profile. The announcement highlights a potential innovation in dermatology treatment, although no clinical efficacy figures, regulatory status, commercial timeline, or financial impact were provided.